PTEN and metastatic prostate carcinoma: Consistent with a possibility of potential cooperation between MME and PTEN in suppression of carcinogenesis, downregulation of MME is observed in 42% and 63% of PTEN-deficient cases of human primary and metastatic prostate cancers, respectively26.